NCT00883480View on ClinicalTrials.gov

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

NACompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

November 30, 2008

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Docetaxel

Docetaxel 75 mg/day 1 x 4 cycles

DRUG

Cisplatin

Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles

DRUG

Gemcitabine

"Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles"

DRUG

Erlotinib

Erlotinib 150 mg/day x 21 days

Trial Locations (2)

08916

Ico-Hospital Universitarios Germans Trias I Pujol, Badalona

Unknown

Hospital Carlos Haya, Málaga

All Listed Sponsors
lead

Spanish Lung Cancer Group

OTHER

NCT00883480 - Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma | Biotech Hunter | Biotech Hunter